The DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.
The microenvironmental and metabolic aspects of sorafenib resistance in hepatocellular carcinoma
Open accessAbstract
In most cases, sorafenib-resistant HCC cells exhibit significant mesenchymal phenotype and stemness features. In this context, tumor cells might undergo cell fate transition in response to sorafenib or other targeted drugs in the presence or absence of genetic mutations. Therefore, understanding the major characteristics of drug-resistant cells state helps to discover new treatments that overcome drug resistance. To note, little is known about the metabolic or microenvironmental aspects of the certain tumor cell states beyond the genome. This review mainly focuses on the underlying mechanisms of acquired sorafenib resistance based on CSCs and EMT models, which explain tumor heterogeneity and have been considered the major cause of secondary sorafenib resistance. In particular, it discusses how the tumor microenvironment and tumor metabolism regulate cell stemness, mesenchymal state, and sorafenib resistance through epigenetic regulations, and provides reliable targets that might have synergetic effect with sorafenib.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Sorafenib in advanced hepatocellular carcinoma
Llovet, J. M., Ricci, S., Mazzaferro, V., Hilgard, P., Gane, E., Blanc, J.-F., de Oliveira, A. C., Santoro, A., Raoul, J.-L., Forner, A., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0708857 · Cited by 13,097
Cheng, A.-L., Kang, Y.-K., Chen, Z., Tsao, C.-J., Qin, S., Kim, J. S., Luo, R., Feng, J., Ye, S., Yang, T.-S., et al. (2009) · The Lancet Oncology · doi:10.1016/s1470-2045(08)70285-7 · Cited by 5,832
Self-citationSun, X., Ou, Z., Chen, R., Niu, X., Chen, D., Kang, R., & Tang, D. (2016) · Hepatology · doi:10.1002/hep.28251 · Cited by 2,012
Tumour micro-environment elicits innate resistance to RAF inhibitors through HGF secretion
Straussman, R., Morikawa, T., Shee, K., Barzily-Rokni, M., Qian, Z. R., Du, J., Davis, A., Mongare, M. M., Gould, J., Frederick, D. T., et al. (2012) · Nature · doi:10.1038/nature11183 · Cited by 1,771
Zhang, J., Zhang, Q., Lou, Y., Fu, Q., Chen, Q., Wei, T., Yang, J., Tang, J., Wang, J., Chen, Y., et al. (2018) · Hepatology · doi:10.1002/hep.29681 · Cited by 286
Allen, E., Miéville, P., Warren, C. M., Saghafinia, S., Li, L., Peng, M.-W., & Hanahan, D. (2016) · Cell Reports · doi:10.1016/j.celrep.2016.04.029 · Cited by 221 · cited 1×
“The co-existence of hypoxic and normoxic regions has been identified inside tumors in terms of the relative proximity to blood vessels in vivo [58].”
Background
Cited by
The immunological and metabolic landscape in primary and metastatic liver cancer
Li, X., Ramadori, P., Pfister, D., Seehawer, M., Zender, L., & Heikenwalder, M. (2021) · Nature Reviews Cancer · doi:10.1038/s41568-021-00383-9 · Cited by 616
Yao, L., Zhao, M.-M., Luo, Q.-W., Zhang, Y.-C., Liu, T.-T., Yang, Z., Liao, M., Tu, P., & Zeng, K.-W. (2022) · ACS Nano · doi:10.1021/acsnano.2c01619 · Cited by 289
Xu, J., Wan, Z., Tang, M., Lin, Z., Jiang, S., Ji, L., Gorshkov, K., Mao, Q., Xia, S., Cen, D., et al. (2020) · Molecular Cancer · doi:10.1186/s12943-020-01281-8 · Cited by 287
Self-citation
Metadata
- Authors
- Xia, S., Pan, Y., Liang, Y., Xu, J., & Cai, X.
- Venue
- EBioMedicine
- Publisher
- Elsevier BV
- Published
- 2020-01
- Volume
- 51
- Pages
- 102610
- ISSN
- 2352-3964 (ISSN-L)
- OpenAlex
- W2999483628
- Cited by
- 297
- References
- 6
- FWCI
- 18.09
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: The microenvironmental and metabolic aspects of sorafenib resistance in hepatocellular carcinoma. https://app.cochat.ai/papers/10.1016/j.ebiom.2019.102610
- The paper
- Xia, S., Pan, Y., Liang, Y., Xu, J., & Cai, X. (2020). The microenvironmental and metabolic aspects of sorafenib resistance in hepatocellular carcinoma. EBioMedicine. https://doi.org/10.1016/j.ebiom.2019.102610
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.